Gwenaelle Gravis

13PUBLICATIONS
164CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied geophysicsMolecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Feb 06, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Benoit Blanchet, Alicja Puszkiel, Anne Jouinot

|Feb 14, 2025
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.

Nadine Houédé, Thierry Chevallier, François Audenet

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Aug 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon

|Jun 14, 2024
Reply to J.A. Garcia et al.

Susan Halabi, Siyuan Guo, Akash Roy

Pageof 3

Frequent Collaborators

3 joint publications

François Audenet

3 joint publications

Constance Thibault

3 joint publications

Yohann Loriot

2 joint publications

Susan Halabi